Form 4: BeOne CEO Sells 100,000 ADSs Under 10b5-1 Plan

BeOne Medicines Ltd. CEO John Oyler sold 100,000 American Depositary Shares over two days in December 2025, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Summary

• John Oyler, the Chief Executive Officer, Director, and a 10% owner of BeOne Medicines Ltd., executed sales of American Depositary Shares (ADSs).
• A total of 100,000 ADSs were sold across multiple transactions on December 15 and 16, 2025.
• The sales were conducted under a Rule 10b5-1 trading plan, which was adopted on March 12, 2025.
• The weighted average sale prices for these transactions ranged from approximately $300.22 to $314.98 per ADS.
• Following these transactions, John Oyler's direct beneficial ownership of American Depositary Shares is 0.
• He retains significant indirect beneficial ownership of Ordinary Shares through various trusts and an investment LLC, totaling 50,995,857 Ordinary Shares, though beneficial ownership is disclaimed for a majority of these holdings.
• Each American Depositary Share represents 13 Ordinary Shares.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to significant insider selling by the CEO, even though it was pre-planned. While a 10b5-1 plan mitigates the immediate negative signal, a complete divestment of direct ADS holdings by a key executive can still raise questions among investors.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and transparent divestment strategy rather than an immediate reaction to new, undisclosed information.

Negatives

• Significant insider selling by the CEO and a 10% owner could be perceived negatively by the market, potentially signaling a desire to diversify holdings or a lack of confidence.
• The sale of 100,000 ADSs represents a complete divestment of the CEO's direct holdings in American Depositary Shares.

Risks

• Potential negative market perception due to significant insider selling by the CEO, which could lead to downward pressure on the stock price.

Future Outlook

N/A

Industry Context

This Form 4 filing reports a routine insider transaction under a pre-arranged plan and does not provide information to assess broader industry trends or competitive landscape.

Related Party Transactions

• John Oyler disclaims beneficial ownership of 481,533 Ordinary Shares held by the P&O Trust, whose beneficiaries include his child.
• John Oyler disclaims beneficial ownership of 7,722,480 Ordinary Shares held in a grantor retained annuity trust, where his father is a trustee.
• John Oyler disclaims beneficial ownership of 28,204,115 Ordinary Shares held by Oyler Investment LLC, 99% of which is owned by a grantor retained annuity trust where his father is a trustee.
• John Oyler disclaims beneficial ownership of 102,188 Ordinary Shares held by The John Oyler Legacy Trust for the benefit of his minor child.

Stakeholder Impact

• Shareholders may interpret the CEO's sale of all direct American Depositary Shares as a signal, potentially influencing investor confidence and stock price.
• The pre-planned nature of the sale (10b5-1 plan) provides transparency and reduces concerns about opportunistic trading, which could be positive for regulatory bodies and corporate governance observers.

Key Dates

Recommendation

While the CEO's sale of all direct American Depositary Shares is a notable event, it was executed under a pre-arranged Rule 10b5-1 trading plan, which suggests a planned diversification or liquidity event rather than a reaction to adverse undisclosed information. The CEO still retains substantial indirect ownership. Without additional company-specific news or broader market context, a 'hold' recommendation is appropriate, advising investors to monitor future company performance and insider activity rather than reacting solely to this planned transaction.

Keywords

BeOne Medicines, ONC, John Oyler, Insider Sale, Form 4, SEC Filing, CEO Stock Sale, 10b5-1 Plan, American Depositary Shares, ADS